OFI
ofi, a leading supplier of naturally good food and beverage ingredients, today unveiled a new sustainability strategy – ‘Choices for Change’ and ambitious 2030 targets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618240708/en/
Choices for Change - new ofi sustainability strategy (Photo: ofi)
Global food brands and retailers are facing growing consumer demand for sustainable products, with increasing weather related and other challenges in the food supply chain and significant new sustainability linked legislation coming up. With ‘Choices for Change’, ofi will provide these companies and their consumers with specific choices to deliver long-term impact across four critical pillars: Prosperous Farmers, Thriving Communities, Climate Action, and Regenerating the Living World.
Every 2030 target in the Choices for Change strategy delivers on key customer needs, including:
- Delivering enhanced livelihood support to one million farmers, helping them to be more productive and deliver better quality ingredients.
- Cutting scope 3 emissions by 30% to offer customers verifiable, low-carbon products and ingredients and contribute to net-zero commitments.
- Bringing 2 million hectares of land under regenerative farming practices to create long-term farm resilience and products with verified positive natural impact.
To give customers more rigorous, verifiable data for sustainability decision-making and reporting, the strategy incorporates a focus on supply chain excellence. This brings traceability, data insights, risk mitigation, verification, and in-depth supplier engagement together to enable the right choices and includes ofi’s suite of award-winning tech tools like AtSource - the sustainability management system and its built in Carbon Scenario Planner for planning and costing climate action.
Launching Choices for Change on UN Sustainable Gastronomy Day, Roel van Poppel, Chief Sustainability Officer, ofi, said: “Choices for Change is the next phase in our journey, building upon and reinforcing years of experience in managing sustainability programs spanning hundreds of farming communities. Our team of over 500 sustainability experts from Côte d’Ivoire to Brazil, from Vietnam to Ghana, bring a deep understanding of and capability to solve some of the key environmental and humanitarian challenges in the food system. We offer our customers and partners the traceability, insights, capability, and choices to drive positive change.”
ofi’s leading global product platforms - cocoa, coffee, dairy, nuts, and spices - already have specific strategies or programs to address the challenges and opportunities of each product supply chain1. These strategies will be integral to delivering the targets under Choices for Change which seeks to consolidate a single set of ambitions to be implemented globally, with universal metrics and definitions for all of ofi’s operations across ~50 countries. It will be delivered in partnership with farmers, governments, civil society and ofi’s customers – including many of the world’s largest food retailers, brands, and manufacturers. ofi has a long history of partnering with customers to deliver shared sustainability goals and scale impact, with over 130 collaborative programs active today.
CEO of ofi, A. Shekhar, said: “We know that doing what’s right for communities and the planet is even more critical to our long-term commercial imperative to deliver the highest quality of food ingredients and solutions to our customers. It equips them with a powerful provenance narrative for their consumers, the people who enjoy delicious, high-quality and sustainable food and beverage products every day around the world.”
Today, ofi will be joined by Mars, the U.S. Agency for International Development, and the Sustainable Food Lab at an Innovation Forum event ‘Making Choices for Change in the global food system’2 to discuss how the food value chain can work together to make better choices at every stage from plant to palate.
The new Choices for Change strategy and the detailed ambitions supporting it can be accessed on ofi’s website.
References
- ofi's existing product-focused sustainability strategies include Cashew Trail, Cocoa Compass, Coffee LENS, Hazelnut Trail, Almond Trail and Dairy Tracks
- Register for the webinar free here.
About ofi
ofi (olam food ingredients) is a new operating group born out of Olam Group. ofi offers sustainable, natural, value-added food products and ingredients so that consumers can enjoy the healthy and indulgent products they love. It consists of industry-leading businesses of cocoa, coffee, dairy, nuts, and spices. ofi has built a unique global value chain presence including its own farming operations, farm-gate origination, and manufacturing facilities. ofi partners with customers, leveraging its complementary and differentiated portfolio of ‘on-trend’ food products, to co-create solutions that anticipate and meet changing consumer preferences as demand increases for healthier food that’s traceable and sustainable. To subscribe to the ofi newsroom, please visit www.ofi.com/news-and-events (privacy statement here). If you do not wish to receive information from ofi please contact media@ofi.com. Follow @ofi-group on LinkedIn.
About Olam
Olam Group is a leading food and agri-business supplying food, ingredients, feed, and fibre to 20,200 customers worldwide. More information on Olam can be found at www.olamgroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618240708/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom